Page 133 - Read Online

Page 10 of 12 An et al. Hepatoma Res 2023;9:43 https://dx.doi.org/10.20517/2394-5079.2023.60

REFERENCES
1. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015;29:221-32. DOI PubMed
2. Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2012;28:266-72. DOI
PubMed PMC
3. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013;145:1215-29. DOI
PubMed PMC
4. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the
rise. Oncologist 2016;21:594-9. DOI PubMed PMC
5. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-25. DOI PubMed
6. Sapisochin G, Javle M, Lerut J, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma:
working group report from the ILTS transplant oncology consensus conference. Transplantation 2020;104:1125-30. DOI
7. Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery
2013;153:811-8. DOI PubMed PMC
8. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic
cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014;149:565-74. DOI PubMed
9. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010;362:1273-81. DOI
10. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a
comparative multicentre study in Japan. Br J Cancer 2010;103:469-74. DOI PubMed PMC
11. Oh D, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with
gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. JCO 2022;40:378.
DOI
12. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a
phase 2 clinical trial. JAMA Oncol 2019;5:824-30. DOI PubMed PMC
13. Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced
cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7:1669-77. DOI
14. Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precis
Oncol 2018;2:1-12. DOI
15. Goyal L, Meric-Bernstam F, Hollebecque A, et al; FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-Rearranged
intrahepatic cholangiocarcinoma. N Engl J Med 2023;388:228-39. DOI
16. Kan Z, Madoff DC. Liver anatomy: microcirculation of the liver. Semin Intervent Radiol 2008;25:77-85. DOI PubMed PMC
17. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969-77. PubMed PMC
18. Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current
techniques in interventional radiology and personalized dosimetry. Br J Radiol 2016;89:20150943. DOI PubMed PMC
19. Ariel IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90
radiating microspheres). Ann Surg 1965;162:267-78. DOI PubMed PMC
20. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere
brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys
2007;68:13-23. DOI PubMed
21. Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology
2011;259:641-57. DOI PubMed PMC
22. Leung WT, Lau WY, Ho SK, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m
macroaggregated albumin. J Nucl Med 1994;35:70-3. PubMed
23. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-
microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995;33:919-24. DOI
24. Collins J, Salem R. Hepatic radioembolization complicated by gastrointestinal ulceration. Semin Intervent Radiol 2011;28:240-5. DOI
PubMed PMC
25. Estes DJ, Wideroff GA, Sendzischew Shane MA, Sussman DA. Yttrium-90 radioembolization: an unusual cause of radiating
abdominal pain. ACG Case Rep J 2019;6:1-2. DOI PubMed PMC
26. Rafi S, Piduru SM, El-Rayes B, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic
cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013;36:440-8. DOI
27. Bourien H, Palard X, Rolland Y, et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-
center experience. Eur J Nucl Med Mol Imaging 2019;46:669-76. DOI
28. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a
preliminary assessment of this novel treatment option. Ann Surg Oncol 2010;17:484-91. DOI PubMed
29. Hoffmann RT, Paprottka PM, Schön A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable
intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012;35:105-16. DOI
30. Buettner S, Braat AJAT, Margonis GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter
retrospective analysis. J Vasc Interv Radiol 2020;31:1035-43.e2. DOI